Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts; Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts.
J Am Coll Cardiol. 2018 Apr 10;71(14):1501-1510. doi: 10.1016/j.jacc.2018.01.069.
Several recent studies have suggested an increased cancer risk among patients with heart failure (HF). However, these studies are constrained by limited size and follow-up, lack of comprehensive data on other health attributes, and adjudicated cancer outcomes.
This study sought to determine whether HF is associated with cancer incidence and cancer-specific mortality.
The study assembled a cohort from the Physicians' Health Studies I and II, 2 randomized controlled trials of aspirin and vitamin supplements conducted from 1982 to 1995 and from 1997 to 2011, respectively, that included annual health evaluations and determination of cancer and HF diagnoses. In the primary analysis, the study excluded participants with cancer or HF at baseline and performed multivariable-adjusted Cox models to determine the relationship between HF and cancer, modeling HF as a time-varying exposure. In a complementary analysis, the study used the landmark method and identified cancer-free participants at 70 years of age, distinguishing between those with and without HF, and likewise performed Cox regression. Sensitivity analyses were performed at 65, 75, and 80 years of age.
Among 28,341 Physicians' Health Study participants, 1,420 developed HF. A total of 7,363 cancers developed during a median follow-up time of 19.9 years (25th to 75th percentile: 11.0 to 26.8 years). HF was not associated with cancer incidence in crude (hazard ratio: 0.92; 95% confidence interval: 0.80 to 1.08) or multivariable-adjusted analysis (hazard ratio: 1.05; 95% confidence interval: 0.86 to 1.29). No association was found between HF and site-specific cancer incidence or cancer-specific mortality after multivariable adjustment. Results were similar when using the landmark method at all landmark ages.
HF is not associated with an increased risk of cancer among male physicians.
几项最近的研究表明心力衰竭(HF)患者的癌症风险增加。然而,这些研究受到规模和随访时间有限、缺乏其他健康属性的综合数据以及裁定的癌症结果的限制。
本研究旨在确定 HF 是否与癌症发病率和癌症特异性死亡率相关。
该研究从 Physicians' Health Studies I 和 II 中组建了一个队列,这是两项分别于 1982 年至 1995 年和 1997 年至 2011 年进行的阿司匹林和维生素补充剂的随机对照试验,包括年度健康评估以及癌症和 HF 诊断的确定。在主要分析中,该研究排除了基线时患有癌症或 HF 的参与者,并进行了多变量调整的 Cox 模型来确定 HF 与癌症之间的关系,将 HF 建模为随时间变化的暴露。在补充分析中,该研究使用了 landmark 方法,并确定了在 70 岁时无癌症的参与者,区分了有无 HF 的参与者,并同样进行了 Cox 回归。在 65、75 和 80 岁时进行了敏感性分析。
在 28341 名 Physicians' Health Study 参与者中,有 1420 人患有 HF。在中位随访时间为 19.9 年(25 至 75 百分位数:11.0 至 26.8 年)期间,共发生了 7363 例癌症。HF 在粗发病率分析(风险比:0.92;95%置信区间:0.80 至 1.08)或多变量调整分析(风险比:1.05;95%置信区间:0.86 至 1.29)中与癌症发病率均无关联。多变量调整后,HF 与特定部位癌症发病率或癌症特异性死亡率之间也没有关联。当在所有 landmark 年龄使用 landmark 方法时,结果均相似。
HF 与男性医生癌症风险增加无关。